Anti-hemophilic factor (human)  was initially approved by the United States Food and Drug Administration on  April 1, 1999.

Anti-hemophilic factor (human)is primarily used to treat hemophilia A, a bleeding disorder resulting from a clotting factor deficiency. It also manages bleeding episodes and provides prophylactic treatment to prevent spontaneous bleeding in individuals with hemophilia A.

Anti-hemophilic factor (human) is administered intravenously (IV) through either peripheral venous access for home use or central venous access devices for those with frequent bleeding episodes or difficult peripheral venous access. 

Side effects of the Anti-hemophilic factor (human) include common reactions like mild infusion site discomfort, fever, headache, and occasional chills. Serious side effects may involve allergic reactions, the development of inhibitors, thromboembolic events (blood clots), and circulatory overload.

If an Anti-hemophilic factor (human) is not administered as prescribed or if inhibitors develop, it may result in inadequate control of bleeding episodes, leading to prolonged or recurrent bleeding. In some cases, individuals with hemophilia A may develop inhibitors (neutralizing antibodies) against it. It can also increase the risk of thromboembolic events, such as deep vein thrombosis (DVT) or pulmonary embolism (PE), especially in individuals with risk factors for clot formation. Some individuals may experience allergic reactions to it, including symptoms like hives, itching, swelling of the face or throat, difficulty breathing, or anaphylaxis (a severe, life-threatening allergic reaction).

Those with a known hypersensitivity to Anti-hemophilic factors (human)or any components should avoid its use. Individuals, especially those with severe hemophilia A, require regular monitoring for the development of inhibitors (neutralizing antibodies).  Patients with a history of thrombosis or clotting disorders should use it cautiously.

When using an Anti-hemophilic factor (human), it is important to be cautious of potential allergies, watch for inhibitors that can reduce its effectiveness, and take care if you have had blood clots or heart issues before. Kids and older adults might need different doses, and if you are pregnant or breastfeeding, consult your doctor. Proper storage, careful driving, and alcohol moderation are important. Watch for infection signs and plan for surgery. Learn how to use it correctly, discuss travel plans with your healthcare team, and seek support for your mental well-being. Inform your doctor about all medications if needed. In emergencies, know what to do for immediate bleeding control.

1. KD Tripathi, Essentials of Medical Pharmacology, Drugs affecting coagulation, bleeding, and thrombosis, 7th edition, 2013, 217.
2. Grifols Therapeutics Inc, [Revised on August 2012] [ Accessed on  15th Sept 2023], https://www.koate-dvi.com/documents/385822/0/Koate_DVI.pdf/fb455459-5ac0-43d3-bb48-363389a7c5c3?t=1414164745000
3. Baxter Healthcare Corporation, US Food and Drug Administration, [Revised on March 2010] [ Accessed on 15th Sept 2023], https://www.fda.gov/media/78280/download

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.